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Immunohistochemical and serological evidence for the role of
streptococcal proteinase in acute post-streptococcal glomerulone-
phritis.
Background. We have previously demonstrated the preferential
secretion of streptococcal proteinase or streptococcal pyrogenic
exotoxin B (SPEB) by nephritic strains of Group A streptococci
isolated from the skin or throat of patients with acute post-
streptococcal glomerulonephritis (APSGN).
Methods. To further explore the possible role of SPEB in
APSGN, we performed ELISA studies to detect anti-SPEB
antibodies in the sera of patients with APSGN, acute rheumatic
fever (ARF), scarlet fever (SF) and normal children. Using
ELISA, anti-SPEB titers on acute and convalescent APSGN sera
were measured to determine immunity to APSGN. We also
performed immunofluorescence studies on APSGN and non-
APSGN kidney biopsies to probe for the presence and localiza-
tion of SPEB.
Results. Our data show that anti-SPEB antibodies are present in
APSGN sera and antibody titers are significantly higher than in
ARF, SF and normal sera. Anti-SPEB titers tend to rise acutely
and decrease with time but do not reach baseline after one year.
When kidney biopsies were probed with rabbit anti-SPEB anti-
body, 12 of 18 (67%) of the APSGN cases were positive while only
4 of 25 (16%) of the non-APSGN cases were positive.
Conclusions. In summary, we were able to demonstrate unique
reactivity to SPEB in human sera and kidney biopsies of APSGN
suggesting a significant role of this toxin in the pathogenesis of
acute post-streptococcal glomerulonephritis.
Acute post-streptococcal glomerulonephritis (APSGN)
has been considered to be an immune-complex mediated
kidney disease that has been strongly associated with throat
or skin infections with certain nephritogenic strains of
b-hemolytic Group A streptococci. Yet the exact mecha-
nism of how these nephritogenic strains specifically cause
the disease remains to be elucidated. The acute onset of the
disease coupled with the fact that throat or skin infection
produces the same kidney disease strongly suggests that
nephritogenic streptococci might secrete a product unique
to those strains associated with nephritis.
Previous work in our laboratory has identified an extra-
cellular plasmin-binding protein preferentially secreted by
nephritis-associated Group A streptococci [1]. Amino-
terminal sequencing of this 46 kD protein revealed that it
was structurally identical to streptococcal pyrogenic exo-
toxin B (SPEB) and to a molecule previously described as
streptococcal proteinase, which is a cysteine protease found
in broth culture of Group A streptococci.
Streptococcal proteinase was first described by Elliot in
1945 when he noted that Group A streptococci elaborated
an extracellular zymogen (molecular wt 42,000) in culture
that could be transformed into an active proteinase (mo-
lecular wt 28,000) by proteolysis followed by reduction [2].
The active enzyme has the ability to digest streptococcal M
protein, casein, gelatin, human and rabbit fibrin. Under
appropriate culture conditions, the zymogen may constitute
over 95% of the extracellular proteins produced by Group
A streptococci. Reducing conditions (use of thiol com-
pounds such as thioethanol, thioglycolic acids, cysteine or
2,3-dimercaptopropanol) activates the zymogen by reduc-
ing the disulfide bond that links the single half-cystine
residue in the protein to a methanethiol, a volatile mercap-
tan, thus behaving like a sulfhydryl enzyme such as papain.
The zymogen (42 kD) can be autocatalytically cleaved by
the reduced zymogen or by trypsin to become an active
proteinase. This results in the removal of about 100 amino
acids from the amino terminal end of the zymogen yielding
a protein of molecular wt 28 kD in size. In this regard,
streptococcal proteinase behaves like a trypsin enzyme.
Enzyme kinetic studies have shown that streptococcal
proteinase has a high ratio of esterase to peptidase activity
[3]. It is a cationic protein with a pk of 8.5.
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Renewed interest in SPEB as an important toxin in
human disease has demonstrated additional properties
such as its ability to induce high fever and rash, enhance
host susceptibility to lethal effects of other agents, and
stimulate nonspecific T cell proliferation [4]. The active
enzyme can cleave the IL-1b precursor to the active IL-1 (a
major cytokine mediating inflammation), cleaves human
fibronectin and can degrade vitronectin (component of the
extracellular matrix) [5, 6]. Furthermore, it cleaves mono-
cytic cell urokinase receptor to release an active fragment
from the cell surface [7]. Passive and active immunization
of mice against SPEB appears to enhance survival against
virulent strains of Group A streptococci [8]. These findings
are strongly suggestive that SPEB may be involved in the
virulence of Group A streptococci in the human host.
To further explore the possible role of SPEB in the
pathogenesis of APSGN, we performed ELISA studies to
detect the presence of anti-SPEB antibodies in the sera of
patients with APSGN, acute rheumatic fever (ARF), scar-
let fever (SF) and normal children in endemic areas. Using
ELISA techniques, anti-SPEB titers on acute and conva-
lescent sera of APSGN patients were measured to deter-
mine possible immunity to APSGN. We also performed
immunofluorescence studies on kidney biopsy specimens
on APSGN and non-APSGN patients to demonstrate its
presence and localization on human kidneys. The results
clearly demonstrate that antibodies to SPEB are present in
human sera of APSGN patients and may provide immunity
to APSGN and that SPEB localizes in the kidneys where




Purified SPEB (in zymogen form) was obtained from the
extracellular products of a nephritic strain of Group A
streptococcus F203D as previously described [9]. The bac-
teria was initially grown in Todd-Hewitt and adapted to
chemically-defined medium. After centrifugation to re-
move the cells, the supernatant was passed through a
45-micron filter and the filtrate was collected and precipi-
tated with ammonium sulfate to 60% saturation. The
precipitated protein was suspended in 50 mM Tris pH 8.2
and dialyzed twice against 10 liters of similar buffer over-
night to remove the ammonium sulfate. The dialyzed
extracellular products were then passed through a DEAE
column and eluted with 0.2 M NaCl. Further purification
was done using FPLC Mono Q column (Pharmacia Biotech
Inc., Pistacaway, NJ, USA). The purification procedure was
monitored with Western blot using a rabbit polyclonal
antibody against SPEB.
Human sera
Human sera were obtained from The Rockefeller Uni-
versity collection. Sera from children (ages 6 to 14 years of
age) with well-documented sequelae of Group A strepto-
coccal infection like acute rheumatic fever (ARF), acute
scarlet fever (SF) and acute post-streptococcal glomerulo-
nephritis (APSGN) were used. Control sera were age-
matched and were obtained from the same geographical
area as the APSGN patients (Trinidad and Chile). Table 1
summarizes the clinical and laboratory data on these
patients. Children with ARF fulfilled the Jones Criteria for
Diagnosis. APSGN patients had decreased complement,
isolation of group A streptococci from skin lesions, ele-
vated BUN, edema and raised ASO titers. SF patients had
classical rash, pharyngitis, and in most cases isolation of
group A streptococci from the throat. Normal controls had
no signs of a streptococcal infection, negative throat cul-
tures and low ASO titers. All sera were drawn during the
first week of admission to the hospital or in the out-patient
clinic, with the exception of serial bleeds on the thirteen
APSGN patients, who were followed for one year.
Animal sera
Rabbit polyclonal antibodies to purified SPEB (zymogen
form) were produced using standard techniques [10].
Briefly, 100 mg of purified SPEB was suspended in phos-
phate buffered saline (PBS; pH 7.5) and mixed with equal
volume of complete Freund’s adjuvant (Difco Laborato-
ries, Detroit, MI, USA) until a thick emulsion was ob-
tained. The emulsion was injected subcutaneously into New
Zealand White rabbits (5 to 7 lbs in weight) in five to six
different sites. Two rabbits were used for immunization.
Subsequent booster immunizations were done every two
weeks using 100 mg of purified SPEB mixed with incom-
plete Freund’s adjuvant. Test bleeds were obtained every
two weeks and antibody titers against SPEB were deter-
mined using ELISA techniques (see below).
Kidney biopsies
Human kidney biopsies (APSGN and non-APSGN
cases) were obtained from the Rockefeller University col-
lection and Universidad Austral de Chile. All biopsy ma-
terials were previously used to confirm the diagnosis of
APSGN or other renal disease. APSGN cases (10 from skin
infections and 8 from throat infections) were from patients
aged 8 to 23 while non-APSGN cases were from ages 14 to
60. Due to paucity of control biopsies from the same
geographical area as the APSGN cases, we were compelled
Table 1. Clinical and laboratory data on patients with Group A






APSGN 30 5–14 ,50 596
ARF 20 5–18 NL 566
SF 31 5–18 NL 448
Controls 22 5–18 NL 160
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to use specimens obtained from different geographical
areas that are part of the University collection. All biopsy
sections were stored frozen at 270°C until use.
Immunofluorescence studies
Using a cryostat, frozen kidney biopsy tissues were cut
into 5 m slices and fixed in cold acetone for five minutes, air
dried and washed in PBS (pH 7.4) for five minutes.
Blocking with a protein blocking agent (Diftags Kit; Shan-
don Inc., Pittsburgh, PA, USA) was done for 20 minutes.
The sections were then incubated with prediluted anti-
human C3-FITC (Shandon Inc.), prediluted anti-human
IgG-FITC (Shandon Inc.) or anti-SPEB antibodies (1:20
and 1:40 dilution) at room temperature for 30 minutes
inside a humidified chamber. For human complement and
human IgG staining, direct immunofluorescent techniques
were used. For the anti-SPEB staining, indirect immuno-
fluorescence was done using a goat anti-rabbit IgG-FITC
antibody (Sigma Chemical Company, St. Louis, MO, USA)
as the secondary antibody (1:100 dilution) with incubation
at room temperature for 30 minutes. The slides were
washed in PBS for five minutes three times and mounted
before viewing with a fluorescence microscope. Preab-
sorbed sera was prepared by incubating 1 mg of purified
SPEB with equal volume of anti-SPEB sera at 37°C for
three hours. The insoluble material was removed by cen-
trifugation at 12,000 rpm 3 15 minutes. The supernatant
was used at 1:20 dilution.
ELISA studies
Into a 96-well microtiter plate (Linbro/Titertek; ICN
Biomedicals Inc., Horsham, PA, USA) purified SPEB (2
mg/ml) in sample buffer (100 mM Tris, pH 9.8) was added at
100 ml per well. The antigen was allowed to bind to the well
by incubating the sealed plate overnight at room tempera-
ture. The plate was then washed for 10 minutes three times
with ELISA wash buffer (10 mM Tris, 500 mM NaCl, 0.05%
Brij 35). The primary antibody (anti-SPEB sera or human
sera in varying dilutions of ELISA wash buffer) was added
and the plate incubated at 37°C for one hour under
humidified conditions. The plate was washed as before. The
secondary antibody, goat anti-rabbit IgG-alkaline phospha-
tase conjugate (Sigma Chemical Co.) or goat anti-human
IgG-alkaline phosphatase conjugate (Sigma Chemical Co.)
diluted at 1:1000 in ELISA wash buffer, was then added
and the plate incubated at 37°C for one hour under
humidified conditions. After washing the plate as before,
100 ml of the phosphatase substrate solution [Sigma 104
phosphatase tablets dissolved in substrate buffer (1 M Tris,
pH 9.8, 1 mM MgCl2) at 1 mg/ml] was added to each well
and incubated at 37°C for one hour. The plate was then
read at 405 nm absorbance using a Dynatech MR 4000
ELISA reader (Dynatech Laboratories, Chantilly, VA,
USA). Absorbance readings were corrected against a sam-
ple buffer blank, antigen control and antibody control.
Human sera were first diluted 1:100 and then further
diluted depending on whether the O.D. reading was .1.0.
Complement activation
Total hemolytic complement in the serum was measured
by a standard assay kit for total complement. Venous
specimens of clotted blood (human and rabbit) were col-
lected and placed on ice at 4°C for one hour, centrifuged at
4°C at 2,000 RPM for 10 minutes, the serum removed and
stored at 270°C until use. On the day of the experiment,
the sera were thawed and the control serum (200 ml) was
mixed 1:1 with 200 ml saline. The experimental sample (200
ml) was mixed 1:1 with 200 ml of SPEB containing 200 mg of
SPEB. The samples were incubated for one hour at 37°C,
centrifuged at 5,000 RPM at 4°C for 10 minutes and
assayed for total complement levels.
Statistical analyses
For the ELISA studies comparing the level of anti-SPEB
titers among different groups of Group A streptococcal
infections (AGN, ARF, SF and normal children), the
one-way ANOVA test was used with a 5 0.05 [11]. The null
hypothesis assumes that all the groups have similar levels of
anti-SPEB titers. For comparing the level of anti-SPEB
titers between the convalescent sera of APSGN patients
(after 1 year) and normal children, the t-test was used with
a 5 0.05. For the biopsy studies, the chi-square test [11]
was used to analyze the outcome of the immunofluorescent
staining using the anti-SPEB antibody. The null hypothesis
assumes that all groups have the same frequency of positive
and negative staining. The level of significance was set at a
5 0.05. All the statistical calculations were done using SPSS
Statistical Package (SPSS Inc., Chicago, IL, USA).
RESULTS
Comparative anti-SPEB titers between APSGN, ARF, SF
and normal sera
Human sera from acute cases of acute post-streptococcal
glomerulonephritis (APSGN, N 5 30), acute rheumatic
fever (ARF, N 5 20), scarlet fever (SF, N 5 31) and normal
children (N 5 22) were tested for the presence and level of
anti-SPEB antibodies using ELISA techniques. Table 1
summarizes the clinical and laboratory values for each
group of patients. Results show that significant anti-SPEB
titers were found in the sera of APSGN (mean O.D. 5 700)
patients compared to the other groups (ARF, mean O.D. 5
0.100; SF, mean O.D. 5 0.025, and normal children, mean
O.D. 5 0.025). P value was ,0.001 (Fig. 1A).
Figure 1B summarizes the anti-streptolysin O (ASO)
titers in each patient group in comparison to the anti-SPEB
titers in these patients. As can be seen, all streptococcal
infection groups had significantly elevated ASO titers com-
pared to controls but were not significantly different from
each other.
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When the sera of 13 documented cases of APSGN were
followed for 52 weeks, serial anti-SPEB titers tended to rise
during the first week and peaked during the first and
second weeks following diagnosis. Thereafter, the titers
decreased but remained significantly higher than normal
controls at the end of 52 weeks (Figs. 2 and 3). The P value
was , 0.0001.
Immunofluorescence studies on kidney biopsies
Eighteen APSGN and 25 non-APSGN kidney biopsy
specimens were examined for the presence of SPEB using
an indirect immunofluorescence technique. All the APSGN
cases were from school-aged children, but due to paucity of
non-APSGN cases in children, adult biopsy cases were
obtained as non-APSGN control group. The latter cases
include four normal kidney tissue, 3 membranous nephrop-
athy, 2 IgA nephropathy, 1 crescentic glomerulonephritis, 3
minimal change nephropathy, 1 HIV nephropathy, 1 inter-
stitial nephritis, 3 lupus nephritis, 1 ischemic renal disease
due to renal artery stenosis, 3 hypertensive nephrosclerosis,
1 thin basement membrane disease and 2 diffuse glomer-
ulosclerosis.
All the APSGN kidney biopsies showed extensive depo-
sition of C3 in the mesangial and glomerular capillary
areas, and weak to minimal deposition of human IgG and
IgM. Twelve of the 18 APSGN cases (67%) had positive
immunofluorescence for SPEB when the rabbit polyclonal
anti-SPEB sera was used as the primary antibody. Figure 4
shows the staining pattern of human C3, IgG, IgM, SPEB,
rabbit sera preabsorbed with purified SPEB and staining of
a non-APSGN kidney biopsy section. The staining pattern
with the anti-SPEB shows coarsely granular staining in the
mesangial and glomerular capillary areas. Four of the 25
non-APSGN biopsies (16%) were positive for SPEB. Inter-
estingly, three of the four non-APSGN cases were mem-
branous nephropathy and one case with IgA nephropathy.
None of the four non-APSGN cases that stained with the
anti-SPEB had clinical or serological evidence of recent
streptococcal infection. Preabsorption of the anti-SPEB
sera with purified SPEB abolished the staining for SPEB.
No staining of any of the biopsies was seen with preimmune
rabbit sera. Table 2 summarizes the results. Using the
chi-square analysis to determine the outcome of the stain-
ing, a significant difference was noted among the groups
(P 5 0.0007).
Complement activation studies
Suspecting that SPEB might activate the complement
pathway in the absence of antibody, human and rabbit sera
known to contain little or no antibodies to SPEB were
mixed with purified SPEB (1 mg/ml) in a 1:1 ratio as
described in the Methods section. Table 3 summarizes the
results, and it is clear that SPEB activates complement in
the absence of detectable antibody. These results strongly
suggest that SPEB activates complement via the alternative
pathway.
DISCUSSION
In this report, we demonstrated the presence of signifi-
cant anti-SPEB titers in APSGN patients compared to
other inflammatory sequelae of Group A streptococcal
infection (acute endemic areas of APSGN). We have also
shown in a group of 13 documented cases of APSGN that
the anti-SPEB titers tend to rise and peak during the first
two weeks of onset of disease and then lower with time.
However, the titers do not reach baseline levels of controls
and remained significantly higher even after a year of
follow-up (Figs. 2 and 3). These findings correlate quite
well with the well known clinical observation that recur-
rences of APSGN are extremely rare and one attack usually
confers life long immunity.
Using indirect immunofluorescence techniques, 67% of
APSGN kidney biopsy specimens stained for SPEB while
Fig. 1. (A) Anti-SPEB titers in sera from patients with acute post-
streptococcal glomerulonephritis (APSGN), acute rheumatic fever (ARF),
scarlet fever (SF) and normal children. *P , 0.001. (B) ASO titers from
the same group of patients, indicating a definite serological response to a
streptococcal extracellular product in the streptococcal infections groups.
*P , 0.001 for AGN, ARF and SF vs. normals. P 5 NS vs. AGN, ARF and
SF.
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only 16% of non-APSGN biopsies were positive for SPEB.
The diffuse granular staining of the mesangial and endo-
capillary areas of the glomeruli suggests the possible affin-
ity of the antigen to these areas of the glomeruli. These
immunofluorescent findings coupled with the serological
reactivity to SPEB strongly suggest a causal role for this
protein in the pathogenesis of APSGN.
When our results are compared to other reports concern-
ing the immunological response to SPEB, certain discrep-
ancies appear. While it is well known that all group A
streptococci contain the gene for SPEB [12], Poon-King et
al clearly showed that nephritis associated strains prefer-
entially secreted the SPEB protein in the extracellular
products when compared to non-nephritis associated
strains [1]. Thus, expression of the SPEB protein in this
particular strain may be crucial to the development of
APSGN and the subsequent immunological response to
this antigen in these patients. Support for this concept is
found in the work of Vogt et al, who also found a unique
serological response to their cationic protein (now known
to be SPEB) in APSGN patients compared to normals and
rheumatic fever patients [13].
In contrast to these results, both Holm et al [14] and
Norrby-Telgrud et al [15] have noted the presence of
significant levels of SPEB antibodies in the sera of normal
patients, patients with tonsillitis, women in the first trimes-
ter of pregnancy, and patients with streptococcal toxic
shock syndrome. The fact that the majority of their patients
were adults (age range 21 to 55) and our patients primarily
were children (5 to 15 years old) might explain the fact that
antibodies to SPEB were more often seen in adult patients
irrespective of the infection. It might also explain the well
known clinical observation that APSGN is primarily a
disease of childhood, since normal children of this age
group have generally low titers to this streptococcal pro-
tein.
Acute post-streptococcal glomerulonephritis (APSGN)
had been classically described as an immune-complex renal
disease following a Group A streptococcal throat or skin
infection. Although certain serological types of Group A
streptococci have been strongly associated with this disease
[16], not all strains within a given nephritogenic type cause
nephritis. This suggests that a unique streptococcal product
is being elaborated only by certain strains (irrespective of
the M protein serotypes) originating from the of skin or
throat, which may lead to the clinical and pathological
picture seen in APSGN.
Numerous investigations for the past decades have fo-
cused on identifying and characterizing the nature of the
streptococcal antigen(s) that may be responsible for incit-
ing the inflammation of the kidneys. Andres et al identified
a streptococcal antigen(s) in glomeruli of APSGN patients
that appeared to be from the streptococcal cell wall [17].
Lange et al identified a cytoplasmic antigen called en-
dostreptosin in glomeruli [18], and antibodies to this anti-
gen were significantly higher in sera from patients [19]. An
important and often overlooked point is that all investiga-
tors noted that biopsies taken early during the course of the
disease rarely revealed the presence of antibody but did
Fig. 2. Serial anti-SPEB titers in the sera of
patients with APSGN. N 5 13 cases.
Fig. 3. Comparison of anti-SPEB titers between convalescent APSGN
sera (after 1 year) and normal sera. P , 0.0001 by the t-test.
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exhibit large deposits of complement and antigen alone [13,
18].
Most important to the present studies were a series of
observations by Vogt and colleagues [13] in which they
reported the presence of a streptococcal extracellular prod-
uct they called “the cationic extracellular streptococcal
antigen.” This antigen was localized in 8 of 18 kidney
biopsies from patients with APSGN. Significantly elevated
levels of antibodies to this cationic antigen were also
present in the sera of APSGN patients. Vogt later acknowl-
edged that this cationic antigen was structurally identical to
streptococcal proteinase or SPEB (personal communica-
tion). Yoshizawa et al also reported a 43 kD pre-absorbing
streptococcal antigen (PA-Ag) identified in kidney biopsies
that appeared to activate the alternative complement path-
way [20]; However, a partial sequence of this antigen
revealed no homology with SpeB or streptococcal protein-
ase.
In this laboratory, Villarreal et al identified a nephritis
strain-associated protein present in the extracellular prod-
ucts of nephritic strains of Group A streptococci [21]. Using
a rabbit polyclonal antibody against this 46 kD protein, they
demonstrated positive staining in 14 of 21 APSGN kidney
biopsies and negative staining in 15 non-APSGN biopsies.
Serological studies also revealed that APSGN patient’s sera
reacted preferentially with the antigen, while only 20% of
acute rheumatic fever and impetigo sera were positive [22].
Subsequent studies by Johnston and Zabriskie [9] identified
a similar protein from the extracellular products of the
same nephritic strains used by Villarreal et al. Amino
terminal sequencing of the presumed nephritis strain-
associated protein revealed it to be a streptokinase and
Fig. 4. Immunofluorescent staining of kidney biopsy section of one case of APSGN using different antibodies (340). (A) Extensive deposition of C3
in mesangium and glomerular capillary walls. (B and C) Minimal staining for IgG and IgM. (D) shows extensive deposition of SPEB in mesangium and
glomerular capillary wall. Staining for SPEB can be abolished by pre-absorbing the rabbit sera against purified SPEB (E). (F) The absence of SPEB in
a non-APSGN kidney biopsy section. (case of IgA nephropathy).
Table 2. Immunofluorescent results of staining for SPEB in APSGN
and non-APSGN biopsies
Biopsy
specimens Anti-SPEB (1) Anti-SPEB (2) Total
APSGN 12 (67%) 6 (33%) 18
Non-APSGNa 4 (16%) 21 (84%) 25
P 5 0.0007 (chi-square analysis). Abbreviations are: SPEB, streptococ-
cal proteinase; ASPGN, acute post-streptococcal glomerulonephritis.
a Defined as normal kidney tissue, membranous nephropathy, IgA
nephropathy, vasculitis, minimal change, lupus nephritis, nephrosclerosis,
ischemic renal disease, crescentic GN, interstitial nephritis, or thin
basement membrane disease
Table 3. Total hemolytic complement levels in human and rabbit sera







a) 200 ml 20 Saline 200 ml 36 mg % 0%
b) 200 ml 20 SPEBa 200 ml 18 mg % 250%
II. Rabbit
a) 200 ml 0 Saline 200 ml 20 mg % 0%
b) 200 ml 0 SPEBa 200 ml , 10 mg %b .250%
a Contained 200 mg SPEB
b Less than dectable range
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biochemical analysis confirmed its ability to act as plasmin-
ogen activator. Mezzano et al, however, failed to demon-
strate unique reactivity to streptococcal streptokinase in
either the sera or kidney biopsies of patients with APSGN
[23]. This suggested that Villarreal’s nephritis strain-asso-
ciated protein was immunologically different from strep-
tokinase.
Because of these discrepancies, Poon-King et al re-
examined the extracellular product of the same nephritic
strains of Group A streptococci that Villarreal and
Johnston studied and isolated a 46 kD protein band on
SDS-PAGE gels unique to these strains [1]. Amino termi-
nal sequencing of the purified protein revealed it to be
100% homologous to the precursor of streptococcal pyro-
genic exotoxin B (SPEB) and identical to Elliot’s previously
described streptococcal proteinase [24, 25]. In the same
study, the purified protein had the additional property of
being able to bind human plasma in vitro (and hence is
alternatively called nephritis plasmin binding protein).
The fact that both Dr. Vogt and our group have identi-
fied a cationic protein present in the glomeruli of APSGN
patients raises the intriguing concept of the mechanism of
activation of this antigen in the pathway of the disease. As
originally proposed by Batsford et al [25], they suggested
that their cationic protein (now known to be streptococcal
proteinase) could penetrate the negatively charged base-
ment membrane (irrespective of its size) and deposit into
the subepithelial area where it might behave as a “planted
antigen” with subsequent activation of the complement
system either alone or later as an antigen-antibody com-
plex. It has been known that cationized macromolecules
(such as ferritin, 500 kD) can penetrate the negatively
charged basement membrane and it was determined that
antigens of 40 to 1000 3 103 daltons in size and with pI
greater than 8.5 to 9.0 can accumulate in the glomerular
basement membrane (GBM) [25]. On the other hand,
soluble immune complexes with net overall positive charges
have been demonstrated in the GBM while anionic or
neutral immune complexes tend to remain in the capillary
side of GBM or in the mesangium [26–31].
Our preliminary observations of the activation of the
alternate complement pathway by SPEB adds further
strength to the “planted antigen” hypothesis. The activa-
tion of the complement cascade via the alternate pathway
would explain the observation by both Vogt and our group
that complement deposition and antigens appear in the
glomeruli long before the appearance of antibody. Subse-
quently, SPEB in combination with antibody could also
deposit complexes in the kidney, or antibody alone could
bind to the foreign planted antigen. Elution studies of
glomerular sections should be able to determine whether
SPEB is still present in the glomeruli after elution of
antibody. The studies would be similar to those carried by
Dixon, Oldstone and Tionetti in experimental immune
complex disease [32].
The other theory is related to the plasmin-binding prop-
erties of SPEB. Group A streptococci have been known to
produce a streptokinase that activates plasminogen to the
active plasmin [33]. This active plasmin when bound to
SPEB is not inactivated by a-antiplasmin. This could
provide a mechanism for invasion of normal tissue barriers
whereby unregulated and excess plasmin in the circulation
may activate complement and inflammation [34]. Both
theories, albeit interesting, will need further experimenta-
tion.
While the exact mechanism whereby streptococcal pyro-
genic exotoxin B (SPEB) alone or in combination with
plasmin initiates the pathology seen in APSGN, the fact
that SPEB plays an important role in APSGN is strength-
ened by the following observations. First, it is expressed in
all nephritic strains noted to date [1]. Secondly, there is a
major serological reactivity to the protein in the sera of
APSGN patients. Thirdly, its presence has been detected in
a high percentage of APSGN biopsies. Finally, at least two
independent investigators have identified the antigen in
APSGN biopsies as SPEB. The molecular weight of the
protein (;43 to 46 kD), its serological reactivity in APSGN
sera and its presence in the biopsies strongly suggest that
the original nephritis strain associated protein, Vogt’s
cationic protein and our nephritis plasmin binding protein
or SPEB (Table 4) are in reality the same nephritogenic
protein and plays a causal role in the pathogenesis of acute
post-streptococcal glomerulonephritis.
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